Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks

Area of Science:

• Oncology
• Radiation Oncology
• Clinical Medicine

Background:

• Early-stage Hodgkin lymphoma is effectively treated with combined chemotherapy and radiation therapy.
• While curative, traditional approaches carry risks of late complications, including second cancers and cardiac disease.
• Older treatment protocols often involved high-dose, wide-field radiation, contributing to these risks.

Purpose of the Study:

• To review the evolution of Hodgkin lymphoma treatment, focusing on radiation therapy advancements.
• To highlight how modern, optimized combined-modality approaches aim to maintain efficacy while reducing treatment-related toxicities.
• To emphasize the shift towards lower radiation doses and smaller fields in current practice.

Main Methods:

• Review of randomized studies and clinical data on Hodgkin lymphoma treatment.
• Analysis of treatment outcomes comparing historical and contemporary approaches.
• Evaluation of the impact of radiation therapy dose and field size on long-term complications.

Main Results:

• Combined-modality treatment, particularly ABVD chemotherapy followed by radiation, offers high cure rates for early-stage Hodgkin lymphoma.
• Modern radiation therapy techniques use lower doses and smaller fields, significantly reducing the risk of second cancers and cardiac disease.
• Even with as few as 2 cycles of ABVD, favorable patients can achieve successful outcomes.

Conclusions:

• Current combined-modality treatment for Hodgkin lymphoma balances high cure rates with minimized long-term risks.
• Optimized chemotherapy and radiation therapy are key to improving patient outcomes and quality of life post-treatment.
• The evolution towards less intensive radiation therapy represents a significant advancement in managing Hodgkin lymphoma.